METHOD FOR BLADDER CANCER COURSE PREDICTION Russian patent published in 2018 - IPC A61B5/1486 

FIELD: medicine.

SUBSTANCE: blood is taken on an empty stomach from the ulnar vein and ELISA is used to detect the presence of IgG antibodies to the following viruses in the serum: Epstein-Barr (EBV) anti-EBV IgG-EBNA, anti-EBV IgG-VCA, anti-EBV IgG-EA, cytomegalovirus (CMV) anti-CMV IgG, herpes simplex virus (HSV) 1 and 2 types of anti-HSV IgG. When any of the following values of antibody levels are detected, it is concluded that there is a significant risk of an adverse course of bladder cancer, regardless of stage and type, in terms of its early recurrence and increased invasive growth. The levels of these antibodies should be as follows: - anti-EBV IgG-EBNA not less than 275 units/ml, - anti-VEB IgG-VCA not less than 583 units/ml, - anti-CMV IgG not less than 670 units/ml, - anti-HSV IgG not less than 19.5 units/ml. When anti-EBV IgG-EA of no more than 10.0 units/ml is detected - a conclusion is made about a reliably favourable prognosis of the bladder cancer course - non-invasive growth and a low risk of tumour recurrence.

EFFECT: method provides accurate, reliable prediction of the of bladder cancer course, regardless of the stage and type of the bladder tumour, unfavourable and favourable course of bladder cancer, using routine immunoassay.

8 dwg, 2 tbl